Psilocybin for Treatment-Resistant Depression: From Phase 2b Success to Phase 3 Realities

Psilocybin — the psychoactive compound in psychedelic mushrooms — has moved from the margins of psychiatry to its clinical mainstream at remarkable speed. The pivotal Phase 2b COMP360 trial (Goodwin et al., 2022), published in the New England Journal of Medicine demonstrated that a single 25-mg dose of synthetic psilocybin produced significant depression reduction in treatment-resistant patients. Now, as Phase 3 trials are underway, the field faces a more complex picture: promising efficacy data alongside serious questions about safety, individual variability, and the practical feasibility of psychedelic-assisted therapy at scale.

The Research Landscape

The Pivotal Phase 2b Trial

Goodwin et al. (2022) conducted the largest randomized controlled trial of psilocybin for treatment-resistant depression (TRD) to date. In this Phase 2b, double-blind trial, 233 adults with TRD were randomized to receive a single dose of COMP360 psilocybin at 25 mg, 10 mg, or 1 mg (control), alongside psychological support from trained therapists.

Key results at 3 weeks:

• 25 mg group: Mean MADRS score decrease of -12.0 points from baseline.
• 10 mg group: Mean decrease of -7.9 points.
• 1 mg control: Mean decrease of -5.4 points.
• Difference (25 mg vs. 1 mg): -6.6 points (95% CI: -10.2 to -2.9, p<0.001).
• Response rate (≥50% improvement) and remission rate (MADRS ≤10) were significantly higher in the 25 mg group at 3 weeks.
• Sustained response at 12 weeks was not statistically significant — a critical finding that tempers enthusiasm.

Adverse events were common (77% of participants), including headache, nausea, and dizziness. Notably, suicidal ideation or behavior occurred in all dose groups, including the 1 mg control — raising questions about whether these events are related to psilocybin itself or to the underlying treatment-resistant depression.

Extended Efficacy Data

Goodwin et al. (2023), published in the Journal of Affective Disorders expand on the Phase 2b primary results with patient-reported outcomes. At Week 3, psilocybin 25 mg was associated with improvements across multiple domains beyond depression severity:

• Reduced anxiety scores.
• Improved positive affect and reduced negative affect.
• Better functioning and reduced disability.
• Improved quality of life.

The 10 mg dose produced smaller effects across all measures. These findings suggest that psilocybin's effects extend beyond depressive symptoms to broader domains of psychological well-being — but the absence of a true placebo and the possibility of functional unblinding (participants who received 1 mg likely knew they did not receive a psychedelic dose) limit interpretation.

Concomitant SSRI Use

A critical clinical question is whether patients must discontinue their existing antidepressants before receiving psilocybin. Goodwin et al. (2023), in Neuropsychopharmacology address this with an open-label study of 19 participants who received 25 mg COMP360 while continuing their SSRI medication.

Results:

• Mean MADRS score change at Week 3: -14.9 points.
• Response and remission: 42.1% of participants met both criteria.
• No serious adverse events and no indication of serotonin syndrome or increased suicidal ideation.

While the small sample size and open-label design limit conclusions, these data are clinically important: requiring SSRI discontinuation before psilocybin treatment introduces withdrawal symptoms and clinical risk, and evidence that concomitant use may be safe opens a more practical treatment pathway.

A Pilot Trial with Mixed Results

Meikle et al. (2025), published in Therapeutic Advances in Psychopharmacology, report a pilot trial of psilocybin therapy for TRD that provides a more granular view of individual variability. Seven participants received two 25 mg psilocybin sessions with preparatory and integration therapy.

At the aggregate level, results were positive: clinically meaningful depression reduction (Hedges' g = -1.27, p = 0.02), maintained at 20-week follow-up. But individual-level data revealed diverse trajectories:

• Two participants showed sustained treatment response.
• Three initially responded but relapsed.
• Two showed no substantial improvement.

Exploratory analyses identified potential predictors: mindset prior to dosing and spiritual/perceptual experiences during the session predicted better outcomes. Treatment expectations, interestingly, did not predict response.

Critical Analysis: Claims and Evidence

<

Claim	Evidence	Verdict
Psilocybin 25 mg reduces depression scores vs. control	Goodwin et al. 2022, Phase 2b RCT, N=233, p<0.001	✅ Supported — strong trial design
Effects extend to anxiety, functioning, quality of life	Goodwin et al. 2023, patient-reported outcomes	✅ Supported — consistent secondary outcomes
Sustained response at 12 weeks	Goodwin et al. 2022, 12-week follow-up	❌ Not supported — failed to reach significance
Psilocybin is safe with concomitant SSRIs	Goodwin et al. 2023, N=19, open-label	⚠️ Preliminary — small sample, no control
Individual response is highly variable	Meikle et al. 2025, pilot trial, N=7	✅ Supported — but very small sample
Mindset predicts treatment response	Meikle et al. 2025, exploratory analysis	⚠️ Hypothesis-generating — needs replication

Open Questions and Future Directions

Durability of response. The 12-week sustained response data from the Phase 2b trial were not significant. If psilocybin's antidepressant effects are transient, the clinical model would require repeated dosing — fundamentally changing the cost-benefit calculation and practical feasibility.

Phase 3 design challenges. Blinding is inherently difficult in psychedelic trials — participants typically know whether they received an active psychedelic dose. Active comparators (rather than micro-dose controls) and innovative blinding strategies are needed.

Therapist training and scalability. All psilocybin trials to date have included intensive psychological support from trained therapists. If psilocybin therapy requires 10+ hours of therapist time per patient (preparation, dosing sessions, integration), scalability is limited and costs are substantial.

Safety in real-world populations. Trial participants are carefully screened for psychotic disorders, substance use disorders, and acute suicidality. Real-world populations are more heterogeneous, and post-marketing safety data will be critical.

The mechanism question. How does psilocybin produce antidepressant effects? Leading hypotheses involve serotonin 2A receptor agonism, increased neuroplasticity, and disruption of rigid cognitive patterns — but the precise mechanism remains unclear, and understanding it is essential for optimizing treatment protocols.

What This Means for the Field

Psilocybin therapy for treatment-resistant depression has moved beyond proof-of-concept. The Phase 2b evidence for acute efficacy is robust, and the safety profile — while requiring careful monitoring — appears manageable. The field now confronts harder questions: Can the effects be sustained? Can the therapeutic model be scaled? Can we identify who will benefit before treatment? And can blinding challenges be resolved sufficiently for regulatory approval?

The Meikle et al. pilot data on individual variability are particularly important. If only 2 of 7 patients show sustained response, the NNT (number needed to treat) may be less favorable than aggregate statistics suggest. Personalized approaches — matching patients to treatments based on predictive biomarkers or psychological profiles — may be necessary to optimize outcomes.

For now, psilocybin remains an investigational treatment. Phase 3 results, expected in the coming years, will determine whether it achieves regulatory approval and enters clinical practice.

Explore related work through ORAA ResearchBrain.

Psilocybin — the psychoactive compound in psychedelic mushrooms — has moved from the margins of psychiatry to its clinical mainstream at remarkable speed. The pivotal Phase 2b COMP360 trial (Goodwin et al., 2022), published in the New England Journal of Medicine demonstrated that a single 25-mg dose of synthetic psilocybin produced significant depression reduction in treatment-resistant patients. Now, as Phase 3 trials are underway, the field faces a more complex picture: promising efficacy data alongside serious questions about safety, individual variability, and the practical feasibility of psychedelic-assisted therapy at scale.

The Research Landscape

The Pivotal Phase 2b Trial

Goodwin et al. (2022) conducted the largest randomized controlled trial of psilocybin for treatment-resistant depression (TRD) to date. In this Phase 2b, double-blind trial, 233 adults with TRD were randomized to receive a single dose of COMP360 psilocybin at 25 mg, 10 mg, or 1 mg (control), alongside psychological support from trained therapists.

Key results at 3 weeks:

• 25 mg group: Mean MADRS score decrease of -12.0 points from baseline.
• 10 mg group: Mean decrease of -7.9 points.
• 1 mg control: Mean decrease of -5.4 points.
• Difference (25 mg vs. 1 mg): -6.6 points (95% CI: -10.2 to -2.9, p<0.001).
• Response rate (≥50% improvement) and remission rate (MADRS ≤10) were significantly higher in the 25 mg group at 3 weeks.
• Sustained response at 12 weeks was not statistically significant — a critical finding that tempers enthusiasm.

Adverse events were common (77% of participants), including headache, nausea, and dizziness. Notably, suicidal ideation or behavior occurred in all dose groups, including the 1 mg control — raising questions about whether these events are related to psilocybin itself or to the underlying treatment-resistant depression.

Extended Efficacy Data

Goodwin et al. (2023), published in the Journal of Affective Disorders expand on the Phase 2b primary results with patient-reported outcomes. At Week 3, psilocybin 25 mg was associated with improvements across multiple domains beyond depression severity:

• Reduced anxiety scores.
• Improved positive affect and reduced negative affect.
• Better functioning and reduced disability.
• Improved quality of life.

The 10 mg dose produced smaller effects across all measures. These findings suggest that psilocybin's effects extend beyond depressive symptoms to broader domains of psychological well-being — but the absence of a true placebo and the possibility of functional unblinding (participants who received 1 mg likely knew they did not receive a psychedelic dose) limit interpretation.

Concomitant SSRI Use

A critical clinical question is whether patients must discontinue their existing antidepressants before receiving psilocybin. Goodwin et al. (2023), in Neuropsychopharmacology address this with an open-label study of 19 participants who received 25 mg COMP360 while continuing their SSRI medication.

Results:

• Mean MADRS score change at Week 3: -14.9 points.
• Response and remission: 42.1% of participants met both criteria.
• No serious adverse events and no indication of serotonin syndrome or increased suicidal ideation.

While the small sample size and open-label design limit conclusions, these data are clinically important: requiring SSRI discontinuation before psilocybin treatment introduces withdrawal symptoms and clinical risk, and evidence that concomitant use may be safe opens a more practical treatment pathway.

A Pilot Trial with Mixed Results

Meikle et al. (2025), published in Therapeutic Advances in Psychopharmacology, report a pilot trial of psilocybin therapy for TRD that provides a more granular view of individual variability. Seven participants received two 25 mg psilocybin sessions with preparatory and integration therapy.

At the aggregate level, results were positive: clinically meaningful depression reduction (Hedges' g = -1.27, p = 0.02), maintained at 20-week follow-up. But individual-level data revealed diverse trajectories:

• Two participants showed sustained treatment response.
• Three initially responded but relapsed.
• Two showed no substantial improvement.

Exploratory analyses identified potential predictors: mindset prior to dosing and spiritual/perceptual experiences during the session predicted better outcomes. Treatment expectations, interestingly, did not predict response.

Critical Analysis: Claims and Evidence

<

Claim	Evidence	Verdict
Psilocybin 25 mg reduces depression scores vs. control	Goodwin et al. 2022, Phase 2b RCT, N=233, p<0.001	✅ Supported — strong trial design
Effects extend to anxiety, functioning, quality of life	Goodwin et al. 2023, patient-reported outcomes	✅ Supported — consistent secondary outcomes
Sustained response at 12 weeks	Goodwin et al. 2022, 12-week follow-up	❌ Not supported — failed to reach significance
Psilocybin is safe with concomitant SSRIs	Goodwin et al. 2023, N=19, open-label	⚠️ Preliminary — small sample, no control
Individual response is highly variable	Meikle et al. 2025, pilot trial, N=7	✅ Supported — but very small sample
Mindset predicts treatment response	Meikle et al. 2025, exploratory analysis	⚠️ Hypothesis-generating — needs replication

Open Questions and Future Directions

Durability of response. The 12-week sustained response data from the Phase 2b trial were not significant. If psilocybin's antidepressant effects are transient, the clinical model would require repeated dosing — fundamentally changing the cost-benefit calculation and practical feasibility.

Phase 3 design challenges. Blinding is inherently difficult in psychedelic trials — participants typically know whether they received an active psychedelic dose. Active comparators (rather than micro-dose controls) and innovative blinding strategies are needed.

Therapist training and scalability. All psilocybin trials to date have included intensive psychological support from trained therapists. If psilocybin therapy requires 10+ hours of therapist time per patient (preparation, dosing sessions, integration), scalability is limited and costs are substantial.

Safety in real-world populations. Trial participants are carefully screened for psychotic disorders, substance use disorders, and acute suicidality. Real-world populations are more heterogeneous, and post-marketing safety data will be critical.

The mechanism question. How does psilocybin produce antidepressant effects? Leading hypotheses involve serotonin 2A receptor agonism, increased neuroplasticity, and disruption of rigid cognitive patterns — but the precise mechanism remains unclear, and understanding it is essential for optimizing treatment protocols.

What This Means for the Field

Psilocybin therapy for treatment-resistant depression has moved beyond proof-of-concept. The Phase 2b evidence for acute efficacy is robust, and the safety profile — while requiring careful monitoring — appears manageable. The field now confronts harder questions: Can the effects be sustained? Can the therapeutic model be scaled? Can we identify who will benefit before treatment? And can blinding challenges be resolved sufficiently for regulatory approval?

The Meikle et al. pilot data on individual variability are particularly important. If only 2 of 7 patients show sustained response, the NNT (number needed to treat) may be less favorable than aggregate statistics suggest. Personalized approaches — matching patients to treatments based on predictive biomarkers or psychological profiles — may be necessary to optimize outcomes.

For now, psilocybin remains an investigational treatment. Phase 3 results, expected in the coming years, will determine whether it achieves regulatory approval and enters clinical practice.

Explore related work through ORAA ResearchBrain.